ARV-766 is identified as an orally available and potent PROTAC that targets the degradation of both the wild-type androgen receptor (AR) and key AR LBD mutants, specifically the prevalent AR L702H, H875Y, and T878A mutations[1].
上海安畢達(dá)生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
邵經(jīng)理